Clinical trial results from the DRCR Retina Network suggest that a specific step strategy, in which patients with diabetic macular edema start with a less expensive medicine and switch to a more expensive medicine if vision does not improve sufficiently, gives results similar to starting off with the higher-priced drug.
Diabetic retinopathy affects nearly 8 million Americans, and that number is expected to double by 2050, but knowing the risks and symptoms and seeking an early diagnosis and treatment from a retina specialist can preserve sight and virtually eliminate vision loss from the condition, according to the American Society of Retina Specialists (ASRS).
America’s retina specialists are warning the public that millions in the US who don’t know the facts about common retinal conditions such as age-related macular degeneration (AMD) and diabetic retinopathy are at risk for preventable blindness or vision loss from these sight stealing conditions.
Optometry researchers have identified new biomarkers that may advance the early detection of diabetic retinopathy, the most common diabetic eye disease and a leading cause of blindness in U.S. adults.
Early treatment with anti-VEGF injections slowed diabetic retinopathy in a clinical study from the DRCR Retina Network (DRCR.net). However, two years into the four-year study its effect on vision was similar to standard treatment, which usually begins at the onset of late disease.
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every other Wednesday.
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every other Tuesday.
Diabetes continues to be the leading cause of new cases of blindness among adults in the United States. But the current shortage of eye-care providers would make it impossible to keep up with demand to provide the requisite annual screenings for this population. A new study looks at the effectiveness of seven artificial intelligence-based screening algorithms to diagnose diabetic retinopathy, the most common diabetic eye disease leading to vision loss.
Surgical and injectable drug approaches are equally effective for treatment of bleeding inside the eye from proliferative diabetic retinopathy (PDR), according to a National Eye Institute (NEI)-supported clinical study from the DRCR Retina Network (DRCR.net).
Sobering new statistics released by the Global Burden of Disease study found no significant reduction in the number of people with treatable sight loss worldwide since 2010 as public health services failed to meet World Health Organization (WHO) targets.
Multiple honors recognize leadership and exemplary scientific and educational contributions
La retinopatía diabética es la causa más común de ceguera en los adultos de edad laboral; sin embargo, la mayoría de los estadounidenses de más de 40 años no conocen sus síntomas ni los factores de riesgo para esta afección común que amenaza la vista, según una encuesta encomendada por la Sociedad Estadounidense de Especialistas en Retina (American Society of Retina Specialists, ASRS).
Diabetic retinopathy is the leading cause of blindness among working-age adults, yet most Americans over 40 don’t know its symptoms or the risk factors for this common sight-threatening condition, according to a survey commissioned by the American Society of Retina Specialists (ASRS).
The American Society of Retina Specialists (ASRS) today announced the launch of a new audio and video podcast series providing consumers with critical information about the signs, symptoms and risk factors of retina disease and the importance of seeing a retina specialist for specialized care.
Innovative device ensures doctors obtain adequate fluid samples from the eye, helping with diagnosis and individualized treatment plans for patients.
New research shows significantly more people with diabetes got their critical annual dilated eye exam during the first two years following Medicaid expansion under the under the Affordable Care Act (ACA). However, this encouraging increase in the exam rate did not persist beyond two years.
Exercise can slow or prevent the development of macular degeneration and may benefit other common causes of vision loss, such as glaucoma and diabetic retinopathy, new research suggests.
Johns Hopkins Medicine scientists say they have successfully turned back the biological hands of time, coaxing adult human cells in the laboratory to revert to a primitive state, and unlocking their potential to replace and repair damage to blood vessels in the retina caused by diabetes. The findings from this experimental study, they say, advance regenerative medicine techniques aimed at reversing the course of diabetic retinopathy and other blinding eye diseases.
Diabetic retinopathy can be diagnosed and graded with the use of a newer scanning technology called ultra-wide field (UWF) imaging, a system that generates high-quality pictures showing most of the retina. Research from the Joslin Diabetes Center’s Beetham Eye Institute has now shown that one technique, UFW fluorescein angiography, detects over three times more microaneurysms than UWF color imaging
With $9.7 million in funding from the National Eye Institute, researchers at the University of Illinois at Chicago will study the impact of chronic eye disease among Latinos.